Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 8/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.50 |
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | TP53 | P04637 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27713231 | 0.98 | ALOX5 (0.51) | ALOX5NPC1ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL824375 | 0.80 | NPC1 (0.69) | ALOX5NPC1ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL29531707 | 0.80 | NPC1 (0.69) | ALOX5NPC1ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL712314 | 0.80 | GAA (0.54) | NPC1ALDH1A1RAB9AHSD17B10HPGD | |
| SCHEMBL11376024 | 0.79 | SMN1; SMN2 (0.48) | ALOX5NPC1ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL8970064 | 0.79 | NPC1 (0.54) | ALOX5NPC1ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL547804 | 0.79 | NPC1 (0.50) | ALOX5NPC1ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL17562381 | 0.75 | ALOX5 (0.67) | ALOX5NPC1ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL15771045 | 0.75 | PTGS2 (0.49) | ALOX5NPC1ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL29117990 | 0.75 | NPC1 (0.46) | ALOX5NPC1ALDH1A1RAB9AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116925090-A | Spiro compound and application thereof in organic light-emitting device and panel | 上海天马微电子有限公司 | 2023-10-24 | — | — | CN | claimed |
| CN-113999220-A | Compound containing benzophenanthrene furan structure and organic electroluminescent device | 南京高光半导体材料有限公司 | 2022-02-01 | — | — | CN | claimed |
| CN-106103497-B | Curable composition, optical component, and compound | 富士胶片株式会社 | 2017-09-05 | — | — | CN | claimed |
| US-9112159-B2 | Bipolar hosts for light emitting devices | NITTO DENKO CORPORATION (JP) | 2015-08-18 | — | — | US | claimed |
| WO-2014093361-A1 | BIPOLAR HOSTS FOR LIGHT EMITTING DEVICES | NITTO DENKO CORPORATION (JP) | 2014-06-19 | — | — | WO | claimed |
| US-20140163237-A1 | BIPOLAR HOSTS FOR LIGHT EMITTING DEVICES | Nitto Denko Corportion (JP) | 2014-06-12 | — | — | US | claimed |
| US-20080187978-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2008-08-07 | — | — | US | claimed |
| US-20080064688-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2008-03-13 | — | — | US | claimed |
| EP-1585734-A4 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS LLC (US) | 2007-09-19 | — | — | EP | claimed |
| EP-1590344-A4 | ANTI-CANCER MEDICAMENTS | DECIPHERA PHARMACEUTICALS LLC (US) | 2007-08-29 | — | — | EP | claimed |
| WO-2006014290-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-02-09 | — | — | WO | claimed |
| US-20050288286-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2005-12-29 | — | — | US | claimed |
| EP-1590344-A2 | ANTI-CANCER MEDICAMENTS | Deciphera Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | claimed |
| EP-1585734-A2 | ANTI-INFLAMMATORY MEDICAMENTS | Deciphera Pharmaceuticals, LLC (US) | 2005-10-19 | — | — | EP | claimed |
| US-20040180906-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2004-09-16 | — | — | US | claimed |
| US-20040176395-A1 | Anti-cancer medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2004-09-09 | — | — | US | claimed |
| WO-2004060305-A2 | ANTI-CANCER MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2004-07-22 | — | — | WO | claimed |
| WO-2004060306-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2004-07-22 | — | — | WO | claimed |
| US-4578469-A | COUMARIN DYES | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-03-25 | — | — | US | claimed |
| US-4208513-A | Benzoxazolyl-phenylstilbenes, processes for producing them, and their use as optical brighteners | CIBA-GEIGY CORPORATION (US) | 1980-06-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064688-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | ALOX5 514/4885NPC1 4549/4885ALDH1A1 3257/4885 |
| US-20050288286-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | ALOX5 514/4885NPC1 4549/4885ALDH1A1 3257/4885 |
| US-20040180906-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | ALOX5 514/4885NPC1 4549/4885ALDH1A1 3257/4885 |
| US-20040176395-A1 | Anti-cancer medicaments | ABL1, ABL2, SRC | ALOX5 3368/4885NPC1 4548/4885ALDH1A1 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.